Why Is Oxford Nanopore Technologies PLC Up Today?

Oxford Nanopore Technologies PLC shares rose 2.48% today to 186.10p, up 4.50p, according to the market data provided.

There does not appear to be a new company announcement behind today's move. The gain comes amid firmer UK mid-cap markets and builds on renewed investor interest since the company's interim results on 19 August, when the shares jumped around 16% as margins and losses improved sharply.

LSE:ONT is now trading well above levels seen before those results as investors warm to its path towards profitability.

Key Highlights

For the six months to 30 June 2026, Oxford Nanopore reported Revenue of £116.7 million, up 12.3% at constant currency and 10.5% on a reported basis. Gross Margin improved by 400 basis points to 62.2%.

The adjusted EBITDA loss narrowed to £22.1 million from £48.3 million a year earlier, showing clear progress towards breakeven. Cash and liquid investments stood at £234.5 million at the end of June.

The company also announced a global cross-licensing agreement expected to generate $20 million of licensing fees in the second half of 2026, plus committed product purchases of $15 million over FY27 and FY28.

About Oxford Nanopore Technologies PLC

Oxford Nanopore is a UK company behind a new generation of molecular sensing technology based on nanopores. Its sequencing devices, from the portable MinION to the high-throughput PromethION, can read DNA and RNA in real time.

Customers span research, biopharma, clinical, applied markets such as food and environment testing, and public health.

Key Reasons Behind Today's Uptick

With no fresh news, today's rise appears linked to broader market strength and continued confidence in the company's turnaround under chief executive Francis Van Parys. Improved margins and a clear timeline to breakeven have reduced some of the concerns that weighed on the shares last year.

Clear Path to Breakeven

Management reiterated its targets for adjusted EBITDA breakeven in FY27 and positive free Cash Flow in FY28. Adjusted operating expenses are expected to be down 2% to flat this year, while gross margin should be around 62%.

This discipline is important because Oxford Nanopore has historically been loss-making and cash-consumptive.

New Strategy and 2030 Targets

The new chief executive set out four strategic priorities, focusing Investment on high-potential applications in biopharma, clinical and research markets. The company introduced a new target of more than $700 million of revenue by 2030, and longer term aims to build a $1 billion-and-growing revenue business.

It also strengthened its Leadership team with a new Chief Medical Officer and Chief Marketing Officer.

Clinical Progress

Oxford Nanopore signed an agreement with MyOme, part of Natera's portfolio, to use its sequencing technology in a rare disease platform. Clinical adoption is a key Long-term Growth opportunity because it can generate recurring Demand for consumables.

Growth Catalysts

Key catalysts include a materially stronger second half, driven by applied markets and secured business, further clinical partnerships and the recognition of the $20 million licensing income. Full-year constant-currency revenue growth guidance is 16% to 20% excluding non-recurring items.

Risks

First-half revenue missed expectations because of weakness in China, disruption in the Middle East and order timing in the Americas. The company remains loss-making and continues to burn cash. Competition from larger sequencing providers is intense.

Iran War and Its Impact on Oxford Nanopore

The Middle East conflict has already affected sales in the region. With Brent Crude above $107 per barrel today, higher Inflation and interest rates could also weigh on research budgets and valuations of growth companies.

However, sequencing demand in public health and biopharma tends to be resilient over the long term.

Valuation

Oxford Nanopore is valued on its growth prospects rather than current earnings. With cash of more than £230 million and a target to reach breakeven next year, the Balance Sheet provides a runway, though investors will want to see steady execution.

What Investors Should Watch Next

Investors should watch second-half revenue growth, China trends, clinical partnerships, cost control and progress towards FY27 breakeven.

Conclusion

Oxford Nanopore's shares continue to recover as the company shows margin progress and a clearer strategy. Today's gain reflects improving sentiment, while delivery of a stronger second half will be key to sustaining the rally.